Johnson & Johnson says its single dose protects against breakthrough Covid-19 for up to 6 months
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer and BioNTech's as well as Moderna. Vials labeled “Covid-19 Coronavirus Vaccine” and syringe are seen in front of displayed Johnson & Johnson logo in this illustration taken, February 9, 2021. Reuters
Johnson & Johnson said on Thursday that a real-world study showed its single shot Covid-19 vaccine protects against breakthrough infections and hospitalisations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer and BioNTech's as well as Moderna.
No waning of protection was found for ICU admissions for all the three vaccines, J&J said.
The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
20.12°C Kathmandu
